Acute myeloid leukemia in the real world: why population-based registries are needed.
about
Post-remission therapy for acute myeloid leukemiaRUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAsAcute myeloid leukaemia: challenges and real world data from IndiaData quality in the Danish National Acute Leukemia Registry: a hematological data resourceAzacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupRisk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry.The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.Easily manageable prognostic factors in 152 Chinese elderly acute myeloid leukemia patients: a single-center retrospective study.Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysisThe caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.Cytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cellsManagement of older or unfit patients with acute myeloid leukemiaRole of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.The benefit of population-based studies for older patients with acute myeloid leukemiaOutcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.Bone marrow transplantation and acute myeloid leukemia: Brazilian guidelines.Physician's Attitude Towards Treatment of Older Patients and the Choice of TherapyInduction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States.Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative databaseTyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience.Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Acute myeloid leukemia in the elderly: do we know who should be treated and how?Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Review of 103 Swedish Healthcare Quality Registries.Epidemiology of chronic myeloid leukaemia: an update.Elderly acute myeloid leukemia: assessing risk.Chemotherapy options for previously untreated acute myeloid leukemia.Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: a retrospective cohort studyEarly mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.Definition of Unfit for Standard Acute Myeloid Leukemia Therapy.Aging: Treating the Older Patient.PD-1 signaling and inhibition in AML and MDS.Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years.
P2860
Q26995867-CF16F6B1-9003-4ECA-B41A-EFD357DE81AAQ27853381-82C81E25-D21A-4910-B33A-FF08C4E08EC0Q28071427-50F7BD87-6FEF-4A3B-A38F-9C17502785D5Q28602934-4B7C9CB4-EDFD-4FC0-8EA3-9698862C5B53Q30667157-0C703AAC-FCA8-44E7-915C-9A5E02250C81Q31163049-21EC9CCC-888F-4E13-9ADA-36403518A3EBQ31169518-BF555ACA-478D-43B7-8EFE-66EE8F6A260BQ33431584-16BC687B-B4F5-4496-878B-2F115B156B4EQ34340772-65C5B8F5-D83C-4333-9286-E8908021D388Q34428556-9ADA88E5-B988-4BF5-8582-D52126DEE8CFQ34527239-C895E809-2B7F-4DE8-A45E-3031184AB36DQ34703798-99169F32-3CAB-4966-8EC6-ECA164B1582CQ34893307-A4D8BF24-0880-496F-8A22-EA06278159C1Q36597388-A33A6C3F-B5D8-4E53-AC2F-04443118E826Q36618933-C29D58B3-F655-4B41-9096-CB40DE16A627Q36662009-5F5F31CD-153A-451C-828C-112DFF07253FQ36723291-E5AA16DB-EEDB-41A8-9502-6211A95BDE43Q36753274-E38C3E91-7358-425E-AD40-A34F690F5386Q36826175-7C10D14D-1724-40DB-ADFC-C6A734AE4ADBQ36828419-2E912F94-C01B-4A77-AD7A-49F3E4298D03Q36934395-CA3D07EC-7E81-43AF-B8CD-A31B0AE4FA9AQ37098856-BE8AA781-30BB-4CB8-BA9E-B8D9B70760EEQ37605585-0C38E62F-45BB-45E9-8327-17C1FD010AA8Q37621352-44B4B374-3D65-4626-A292-FBC8580EA911Q37683373-A0DB84BD-8A47-4601-BFCF-0122CA4A1A40Q38091393-900149B9-4E5D-4C3C-8066-EE511550B703Q38104287-1DDB0520-83B5-466D-91D7-73C2F6738289Q38124066-3446B9BA-837A-42E5-8940-18E0E6472333Q38161965-9474C947-1A25-44F4-BFC0-5D7460542FF0Q38244987-700AE4CD-AB92-476C-9F95-D1BE2167CE9DQ38392709-6E983AA0-F9F1-4FD4-9A02-33C989E5438EQ38458166-A43C0DFE-F5FB-4D84-8E55-777BD6F3B666Q38585930-EEC6BB29-64FB-4892-B59D-A7BA0C784473Q38614756-61196530-52AB-4EBC-807D-62D65BF93BE5Q38642912-ABB5571B-4157-4289-A91B-DB1DB85ED6AAQ38832223-98234AC2-5E30-465F-871B-DFE35C596105Q38967020-FC18A248-FB07-4653-89D4-28615010E8D6Q39013605-439A19EA-DE64-4997-BACB-78365F7171F7Q39393084-17C1B7FE-CB0D-4208-94F3-45691EE8EE7DQ40138696-A68FE715-7A52-4E27-8787-CFFEEF96376A
P2860
Acute myeloid leukemia in the real world: why population-based registries are needed.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Acute myeloid leukemia in the real world: why population-based registries are needed.
@ast
Acute myeloid leukemia in the real world: why population-based registries are needed.
@en
type
label
Acute myeloid leukemia in the real world: why population-based registries are needed.
@ast
Acute myeloid leukemia in the real world: why population-based registries are needed.
@en
prefLabel
Acute myeloid leukemia in the real world: why population-based registries are needed.
@ast
Acute myeloid leukemia in the real world: why population-based registries are needed.
@en
P2093
P2860
P1433
P1476
Acute myeloid leukemia in the real world: why population-based registries are needed.
@en
P2093
Ann-Sofi Hörstedt
Gunnar Juliusson
Martin Höglund
Oskar Hagberg
Swedish Acute Leukemia Registry Group
Vladimir Lazarevic
P2860
P304
P356
10.1182/BLOOD-2011-12-379008
P407
P577
2012-03-01T00:00:00Z